Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 8/20 | 0.37 |
| ▸ | KDM1A | O60341 | 3/20 | 0.35 |
| ▸ | HTR2A | P28223 | 1/20 | 0.34 |
| ▸ | HTR2C | P28335 | 1/20 | 0.34 |
| ▸ | HTR2B | P41595 | 1/20 | 0.34 |
| ▸ | GRIN2B | Q13224 | 2/20 | 0.33 |
| ▸ | BACE1 | P56817 | 1/20 | 0.33 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.33 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.33 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.33 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.33 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.33 |
| ▸ | GRIN3A | Q8TCU5 | 1/20 | 0.33 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL379939 | 1.00 | SIGMAR1 (0.37) | SIGMAR1KDM1AHTR2AHTR2CHTR2B | |
| SCHEMBL380562 | 0.90 | SIGMAR1 (0.35) | SIGMAR1KDM1AHTR2AHTR2CHTR2B | |
| SCHEMBL380563 | 0.90 | SIGMAR1 (0.35) | SIGMAR1KDM1AHTR2AHTR2CHTR2B | |
| SCHEMBL15061443 | 0.81 | SIGMAR1 (0.34) | SIGMAR1KDM1AHTR2AHTR2CHTR2B | |
| SCHEMBL15061315 | 0.76 | MCHR2 (0.46) | SIGMAR1KDM1AHTR2AHTR2CHTR2B | |
| SCHEMBL380882 | 0.74 | KDM1A (0.49) | KDM1A | |
| SCHEMBL783757 | 0.70 | SIGMAR1 (0.39) | SIGMAR1KDM1AHTR2AHTR2C | |
| SCHEMBL15061388 | 0.70 | SIGMAR1 (0.39) | SIGMAR1KDM1AHTR2AHTR2C | |
| SCHEMBL380816 | 0.68 | PRMT5 (0.48) | KDM1A | |
| SCHEMBL14272817 | 0.67 | KDM1A (0.48) | KDM1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8476253-B2 | Amide derivative | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2013-07-02 | — | — | US | disclosed |
| US-20120071467-A1 | AMIDE DERIVATIVE | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2012-03-22 | — | — | US | disclosed |
| EP-2409977-A1 | AMIDE DERIVATIVE | Daiichi Sankyo Company, Limited (JP) | 2012-01-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120071467-A1 | AMIDE DERIVATIVE | CHRM3, CHRM2, TACR2 | SIGMAR1 116/4885KDM1A 1062/4885HTR2A 222/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.